Evidence map›Paper›PMID 37841875›Full record

ArticleResearch square2023

Dual blockade of BRD4 and ATR/WEE1 pathways exploits

Yasuto Kinose, Haineng Xu, Hyoung Kim, Sushil Kumar, Xiaoyin Shan, Erin George, Xiaolei Wang, Sergey Medvedev, Benjamin Ferman, Sarah B Gitto and 14 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 2 countries.

Yasuto KinosePenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Haineng XuPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0001-7195-4897
Hyoung KimPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-9975-8545
Sushil KumarPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Xiaoyin ShanPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Erin GeorgePenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Xiaolei WangPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Sergey MedvedevPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Benjamin FermanPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Sarah B GittoPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Margaret WhickerPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Kurt D'AndreaDepartment of Medicine, Division of Translational Medicine and Human Genetics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Bradley WubbenhorstDepartment of Medicine, Division of Translational Medicine and Human Genetics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Dorothy HallbergThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Mark O'ConnorAstraZeneca, R&D Oncology, Cambridge, United Kingdom.ORCID 0000-0003-1823-625X
Lauren E SchwartzDepartment of Pathology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104.
Wei-Ting HwangDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0003-2829-2167
Katherine L NathansonDepartment of Medicine, Division of Translational Medicine and Human Genetics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-6740-0901
Gordon B MillsDivision of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR.ORCID 0000-0002-0144-9614
Victor E VelculescuThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0003-1195-438X
Tian-Li WangThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Eric J BrownDepartment of Cancer Biology and the Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Ronny DrapkinPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-6912-6977
Fiona SimpkinsPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-0840-2368
Hospital of the University of Pennsylvania · USJohns Hopkins University · USCalifornia University of Pennsylvania · USAbramson Cancer CenterAstraZeneca (United Kingdom) · GBCancer Research Institute · USOregon Health & Science University · US

Funding

SPORE in Ovarian CancerP50CA228991 · NCI · JOHNS HOPKINS UNIVERSITY · PI Ronny I DRAPKIN, IE-MING SHIH · 2018 to 2026
$20.5M
Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancerU01CA217842 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DENEEN, BENJAMIN, MILLS, GORDON B. · 2017 to 2021
$3.6M
Systematic Characterization and Targeting of Neomorphic Drivers in CancerU01CA281902 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Benjamin Deneen, Han Liang · 2023 to 2026
$3.5M
Mechanistic maps of adaptive responses to therapeutic stress to optimize combination therapies.U01CA253472 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORKUT, ANIL, LIANG, HAN · 2021 to 2025
$2.6M
Developing biomarkers of response for a new therapy in ovarian cancerR01CA285965 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Eric J Brown, FIONA SIMPKINS · 2024 to 2026
$2.0M
NCI NIH HHS P50 CA228991NCI NIH HHS R01 CA285965NCI NIH HHS U01 CA217842NCI NIH HHS U01 CA253472NCI NIH HHS U01 CA281902
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ARID1AATRBRD4clear cell ovarian cancerDNA damage responseWEE1

Identifiers

PMID37841875
PMCPMC10571599
OpenAlexW4387094998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.